TOP TIERMARKET NEWSWIRE

News & sentiment

GENMAB A/S ADR (GMAB) — News & AI sentiment

GENMAB A/S ADR (GMAB) news roundup. 27 stories in the past week, 60 over 30 days. Average 30-day sentiment is 64/100. No insider transactions filed in the last 90 days. No congressional trade disclosures in the last 90 days. Data shown on this page is delayed 4 hours. Real-time access — including the live wire, real-time alerts, the live S&P 500 heatmap, and the AI Top Trades long/short board — is available with a Top Tier Newswire Pro subscription.

Public view, delayed 4h. For real-time news, alerts, AI sentiment and the long/short AI Top Trades board:Open in the live terminal →

24h stories

0

7d stories

27

avg sentiment 65.7/100

30d stories

60

avg sentiment 64/100

Insider net (90d)

$0

0 buys · 0 sells

Congress (90d)

0

0 buys · 0 sells

GMAB news in the last 24 hours, 7 days, 30 days and 90 days

How much GMAB coverage the wire captured in each window, with the average AI sentiment across those stories. Counts are of stories that have cleared the 4-hour public delay.

Time window	GMAB stories	Avg AI sentiment	Read
Last 24 hours	0	—	no coverage
Last 7 days	27	65.7/100	GMAB headlines →
Last 30 days	60	64/100	GMAB headlines →
Last 90 days	88	61.9/100	GMAB headlines →

Latest stories on GMAB

Health Care Roundup: Market Talk

WSJ Markets50 · neutralgeneral

1d ago

J.P. Morgan upgrades Genmab on cancer drug growth potential

Investing.com Markets64 · neutralanalyst

1d ago

JPMorgan upgrades Genmab stock rating on drug trial outlook

Investing.com Analyst Ratings64 · neutralanalyst

1d ago

Genmab price target raised to DKK 3,200 from DKK 2,850 at BofA

The Fly64 · neutralanalyst

2d ago

Genmab Price Target Raised To 52 From 43 At Td Cowen

The Fly64 · neutralanalyst

2d ago

Genmab announces updated Phase 2 data on petosemtamab

The Fly63 · neutralproduct/pr

2d ago

Genmab Announces Updated Phase 2 Data Demonstrating More Than Two-Year Median Overall Survival with Petosemtamab Plus Pembrolizumab in First-Line Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

GlobeNewswire74 · bullishproduct/pr

2d ago

Genmab upgraded to Overweight from Neutral at JPMorgan

The Fly63 · neutralanalyst

2d ago

Why is Genmab stock surging today?

Investing.com Markets72 · bullishgeneral

2d ago

Genmab shares jump 13% on colorectal cancer drug trial results

Investing.com Markets74 · bullishproduct/pr

2d ago

Genmab announces updated analyses from Phase 2 trial of petosemtamab

The Fly58 · neutralproduct/pr

3d ago

Incyte, Genmab announce clinical trial collaboration to evaluate INCB161734

The Fly61 · neutralproduct/pr

3d ago

Genmab, Incyte team up to develop experimental colorectal cancer treatment

Seeking Alpha64 · neutralproduct/pr

3d ago

Genmab Announces Updated Follow-Up Analyses from Phase 2 Study of Petosemtamab Demonstrate Meaningful Objective Response Rates in Patients with Metastatic Colorectal Cancer

StockTitan64 · neutralproduct/pr

3d ago

Genmab Announces Updated Follow-Up Analyses from Phase 2 Study of Petosemtamab Demonstrate Meaningful Objective Response Rates in Patients with Metastatic Colorectal Cancer

GlobeNewswire64 · neutralproduct/pr

3d ago

Genmab and Incyte Announce Clinical Trial Collaboration in Metastatic Colorectal Cancer

GlobeNewswire63 · neutralproduct/pr

4d ago

Incyte and Genmab Announce Clinical Trial Collaboration in Metastatic Colorectal Cancer

StockTitan63 · neutralproduct/pr

4d ago

Corcept Therapeutics plunges 20% on Genmab cancer data

Seeking Alpha34 · bearishgeneral

5d ago

Genmab rises, Corcept falls on late-stage antibody-conjugate data for ovarian cancer

Seeking Alpha50 · neutralearnings

5d ago

Why is Genmab stock surging today?

Investing.com Markets72 · bullishgeneral

5d ago

Genmab stock surges 9% following positive phase 3 ovarian cancer trial results

Investing.com Markets78 · bullishproduct/pr

5d ago

Genmab Says Ovarian Cancer Drug Met Two Endpoints in Phase 3 Trial

MarketWatch74 · bullishproduct/pr

5d ago

Genmab says Phase 3 Rainfol-02 trial met primary endpoint of PFS

The Fly74 · bullishproduct/pr

5d ago

Genmab jumps 4$ to $41.61 after ovarian cancer trial data

The Fly74 · bullishproduct/pr

5d ago

Genmab says Phase 3 ovarian cancer trial met primary endpoint

The Fly74 · bullishproduct/pr

5d ago

Open GMAB in the live Top Tier Newswire terminal for real-time stories, sentiment, insider + congress alerts, and the AI Top Trades long/short board.Start a 1-day free trial →